VYLOY Approved in India for First-Line Treatment of Specific Gastric and GEJ Adenocarcinoma
Astellas Pharma India has launched VYLOY (zolbetuximab) combined with chemotherapy for first-line treatment of adult patients in India with HER2-negative, CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma. Approved by the Central Drugs Standard Control Organization, this therapy is supported by Phase 3 SPOTLIGHT and GLOW trials, which showed improved progression-free and overall survival compared to chemotherapy alone. Common side effects included nausea, vomiting, and decreased appetite. An FDA-approved test identifies eligible patients based on CLDN18.2 status.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (60/100). Lens Score 44/100.
Outlets measured: businessstandard, thetribune. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
thetribune broke this story on 30 Jul, 12:07 pm. Other outlets followed.